Prognostic value and clinical significance of halo naevi regarding vitiligo

British Journal of Dermatology

Volumn 164, Issue 4, 2011, Pages 743-749

  Van Geel, Nanja ^a   Vandenhaute, S ^a   Speeckaert, R ^a   Brochez, L ^a   Mollet, I ^a   De Cooman, L ^a   Lambert, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FAMILY HISTORY; FEMALE; HALO NEVUS; HUMAN; ISOMORPHIC PHENOMENON; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SKIN DISEASE; VITILIGO;

ADULT; AGE OF ONSET; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; NEVUS, HALO; PROGNOSIS; QUESTIONNAIRES; SKIN NEOPLASMS; VITILIGO;

EID: 79953676295     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10154.x     Document Type: Article

References (20)

1. Larsson PA, Liden S. Prevalence of skin diseases among adolescents 12-16 years of age. Acta Derm Venereol (Stockh) 1980; 60:415-23. (Pubitemid 11225016)
2. Wayte DM, Helwig EB. Halo nevi. Cancer 1968; 22:69-90.
3. Schallreuter KU, Kothari S, Elwary S et al. Molecular evidence that halo in Sutton's naevus is not vitiligo. Arch Dermatol Res 2003; 295:223-8. (Pubitemid 37452613)
4. Lerner AB. Vitiligo. J Invest Dermatol 1959; 32:285-310.
5. Frank SB, Cohen HJ. The halo nevus. Arch Dermatol 1964; 89:367-73.
6. Gauthier Y, Surleve-Bazeille JE, Gauthier O et al. Ultrastructure of halo nevi. J Cutan Pathol 1975; 2:71-81.
7. van Geel NA, Mollet IG, De Schepper S et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res 2010; 23:375-84.
8. de Vijlder HC, Westerhof W, Schreuder GM et al. Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA association study. Pigment Cell Res 2004; 17:270-4. (Pubitemid 38724557)
9. Kim HS, Goh BK. Vitiligo occurring after halo formation around congenital melanocytic nevi. Pediatr Dermatol 2009; 26:755-6.
10. Stierman SC, Tierney EP, Shwayder TA. Halo congenital nevocellular nevi associated with extralesional vitiligo: a case series with review of the literature. Pediatr Dermatol 2009; 26:414-24.
11. Hofmann UB, Brocker EB, Hamm H. Simultaneous onset of segmental vitiligo and a halo surrounding a congenital melanocytic naevus. Acta Derm Venereol (Stockh) 2009; 89:402-6.
12. Herd RM, Hunter JA. Familial halo naevi. Clin Exp Dermatol 1998; 23:68-9. (Pubitemid 28308367)
13. Chisa N. Multiple halo nevi in siblings. Arch Dermatol 1965; 92:404-5.
14. Gregersen PK. Teasing apart the complex genetics of human autoimmunity: lessons from rheumatoid arthritis. Clin Immunol 2003; 107:1-9. (Pubitemid 36539440)
15. Jin Y, Birlea SA, Fain PR et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362:1686-97.
16. Fain PR, Babu SR, Bennett DC et al. HLA class II haplotype DRB1*04-DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset. Pigment Cell Res 2006; 19:51-7.
17. Liu JB, Li M, Chen H et al. Association of vitiligo with HLA-A2: a meta-analysis. J Eur Acad Dermatol Venereol 2007; 21:205-13. (Pubitemid 46128696)
18. Falchi M, Bataille V, Hayward NK et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009; 41:915-19.
19. Gerstenblith MR, Shi J, Landi MT. Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res 2010; 23:587-606.
20. Hartmann A, Bedenk C, Keikavoussi P et al. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges 2008; 6:1053-9.